Authors' reply to correspondence to "Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium. Ann Endocrinol (Paris). 2023 Aug 31:S0003-4266(23)00685-6. doi: 10.1016/j.ando.2023.08.002".

Orioli, Laura;Servais, Thomas;Crenier, Laurent;Oriot, Philippe;Hermans, Michel;et.al.
(2023) Annales d’endocrinologie — Vol. 84, n° 6, p. 790-791 (2023)

Files

2023_Orioli_Ann_Endocr.pdf
  • Open Access
  • Adobe PDF
  • 237.21 KB
Download

Details

Authors
Show more
Abstract
Authors’ reply: The correspondence raised important concerns regarding the optimization of antidiabetic therapy to improve COVID-19 outcomes for people with type-2 diabetes (T2D). In particular, the authors pointed out the additional benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) beyond glucose control. Recent guidelines for the management of T2D indeed emphasize the use of drugs that promote weight-loss and provide cardiorenal protection: GLP-1 RA and SGLT2i, in association with metformin or not [...].
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Orioli, L., Servais, T., Crenier, L., Oriot, P., Yombi, J. C., & Hermans, M. (2023). Authors’ reply to correspondence to “Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium. Ann Endocrinol (Paris). 2023 Aug 31:S0003-4266(23)00685-6. doi: 10.1016/j.ando.2023.08.002”. Annales d’endocrinologie, 84(6), 790-791. https://doi.org/10.1016/j.ando.2023.10.001 (Original work published 2023)